{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:43:24Z","timestamp":1790747004021,"version":"4.1.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The COVID-19 pandemic resulted in delayed access to medical care. Restrictions to health care specialists, staff shortages, and fear of SARS-CoV-2 infection led to interruptions in routine care, such as early melanoma detection; however, premature mortality and economic burden associated with this postponement have not been studied yet.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the premature mortality and economic costs associated with suspended melanoma screenings during COVID-19 pandemic lockdowns by estimating the total burden of delayed melanoma diagnoses for Europe.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This multicenter economic evaluation used population-based data from patients aged at least 18 years with invasive primary cutaneous melanomas stages I to IV according to the American Joint Committee on Cancer (AJCC) seventh and eighth editions, including melanomas of unknown primary (T0). Data were collected from January 2017 to December 2021 in Switzerland and from January 2019 to December 2021 in Hungary. Data were used to develop an estimation of melanoma upstaging rates in AJCC stages, which was verified with peripandemic data. Years of life lost (YLL) were calculated and were, together with cost data, used for financial estimations. The total financial burden was assessed through direct and indirect treatment costs. Models were building using data from 50\u202f072 patients aged 18 years and older with invasive primary cutaneous melanomas stages I to IV according to the AJCC seventh and eighth edition, including melanomas of unknown primary (T0) from 2 European tertiary centers. Data from European cancer registries included patient-based direct and indirect cost data, country-level economic indicators, melanoma incidence, and population rates per country. Data were analyzed from July 2021 to September 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>COVID-19 lockdown-related delay of melanoma detection and consecutive public health and economic burden. As lockdown restrictions varied by country, lockdown scenario<\/jats:italic> was defined as elimination of routine medical examinations and severely restricted access to follow-up examinations for at least 4 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcomes were the total burden of a delay in melanoma diagnosis during COVID-19 lockdown periods, measured using the direct (in US$) and indirect (calculated as YLL plus years lost due to disability [YLD] and disability-adjusted life-years [DALYs]) costs for Europe. Secondary outcomes included estimation of upstaging rate, estimated YLD, YLL, and DALY for each European country, absolute direct and indirect treatment costs per European country, proportion of the relative direct and indirect treatment costs for the countries, and European health expenditure.<\/jats:p><\/jats:sec>Results<\/jats:title>There were an estimated 111\u202f464 (range, 52\u202f454-295\u202f051) YLL due to pandemic-associated delay in melanoma diagnosis in Europe, and estimated total additional costs were $7.65 (range, $3.60 to $20.25) billion. Indirect treatment costs were the main cost driver, accounting for 94.5% of total costs. Estimates for YLD in Europe resulted in 15\u202f360 years for the 17% upstaging model, ranging from 7228 years (8% upstaging model) to 40\u202f660 years (45% upstaging model). Together, YLL and YLD constitute the overall disease burden, ranging from 59\u202f682 DALYs (8% upstaging model) to 335\u202f711 DALYs (45% upstaging model), with 126\u202f824 DALYs for the real-world 17% scenario.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This economic analysis emphasizes the importance of continuing secondary skin cancer prevention measures during pandemics. Beyond the personal outcomes of a delayed melanoma diagnosis, the additional economic and public health consequences are underscored, emphasizing the need to include indirect economic costs in future decision-making processes. These estimates on DALYs and the associated financial losses complement previous studies highlighting the cost-effectiveness of screening for melanoma.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.56479","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T16:31:25Z","timestamp":1708101085000},"page":"e2356479","source":"Crossref","is-referenced-by-count":19,"title":["Health Economic Consequences Associated With COVID-19\u2013Related Delay in Melanoma Diagnosis in Europe"],"prefix":"10.1001","volume":"7","author":[{"given":"Lara V.","family":"Maul","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel, Basel, Switzerland"},{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Jamiolkowski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel, Basel, Switzerland"},{"name":"Division of Pediatric Dermatology, Children\u2019s Hospital Auf der Bult, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Lapides","sequence":"additional","affiliation":[{"name":"Robert Larner, MD, College of Medicine at the University of Vermont, Burlington, Vermont"},{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina M.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom"},{"name":"The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori, IRCCS, Fondazione G Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, Australia"},{"name":"Royal North Shore Hospital, Sydney, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Charles Perkins Centre, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang-Evers","sequence":"additional","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, Australia"},{"name":"Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Charles Perkins Centre, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Saravi","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Trauma Surgery, Medical Center\u2013University of Freiburg, Germany"},{"name":"Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Navarini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Legge","sequence":"additional","affiliation":[{"name":"Institute of Law and Economics, University of St Gallen, St Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n B.","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University of Szeged, Szent-Gy\u00f6rgyi Albert Medical School, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes J.","family":"J\u00e1nosi","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University of Szeged, Szent-Gy\u00f6rgyi Albert Medical School, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Istituto Oncologico Veneto \u2013 IRCCS, Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Feller","sequence":"additional","affiliation":[{"name":"National Agency for Cancer Registration, University of Zurich, Zurich, Switzerland"},{"name":"Foundation National Institute for Cancer Epidemiology and Registration, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Manstein","sequence":"additional","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zink","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Buja","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Loredan, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaustubh","family":"Adhikari","sequence":"additional","affiliation":[{"name":"School of Mathematics and Statistics, Faculty of Science, Technology, Engineering and Mathematics, The Open University, Milton Keynes, United Kingdom"},{"name":"Department of Genetics, Evolution and Environment, and UCL Genetics Institute, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Roider","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel, Basel, Switzerland"},{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"issue":"12","key":"zoi231665r2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1001\/archderm.142.12.1551","article-title":"Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas.","volume":"142","author":"Liu","year":"2006","journal-title":"Arch Dermatol"},{"issue":"4","key":"zoi231665r3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/jid.2011.433","article-title":"Chronology of metastasis in cutaneous melanoma: growth rate model.","volume":"132","author":"Tejera-Vaquerizo","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"4","key":"zoi231665r4","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jaad.2020.12.065","article-title":"The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers.","volume":"84","author":"Marson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"zoi231665r5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2015.09.016","article-title":"Melanoma burden by melanoma stage: assessment through a disease transition model.","volume":"53","author":"Tromme","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi231665r6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/ajco.v17.4","article-title":"An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.","volume":"17","author":"Degeling","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"zoi231665r7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejca.2021.04.019","article-title":"Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: a national population-based modelling study in England, UK.","volume":"152","author":"Gheorghe","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi231665r8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2340\/00015555-2830","article-title":"Estimation of direct melanoma-related costs by disease stage and by phase of diagnosis and treatment according to clinical guidelines.","volume":"98","author":"Buja","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"36","key":"zoi231665r11","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi231665r13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.v67.6","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi231665r14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jaad.2017.03.018","article-title":"Frequency of and risk factors for tumor upstaging after wide local excision of primary cutaneous melanoma.","volume":"77","author":"Etzkorn","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"zoi231665r15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.clindermatol.2021.05.015","article-title":"The effect of the COVID-19 lockdown on melanoma diagnosis in Italy.","volume":"39","author":"Gualdi","year":"2021","journal-title":"Clin Dermatol"},{"key":"zoi231665r16","article-title":"Trends in skin melanoma burden: findings from the Global Burden of Disease Study.","volume":"22","author":"Siotos","year":"2022","journal-title":"Eplasty"},{"key":"zoi231665r17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jdv.2019.33.issue-S2","article-title":"Cost-of-illness of melanoma in Europe\u2014a modelling approach.","volume":"33","author":"Krensel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"zoi231665r18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/cancers13030408","article-title":"Impact of the COVID-19 pandemic on cancer diagnoses in general and specialized practices in Germany.","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"zoi231665r19","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1111\/jdv.v34.8","article-title":"Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model.","volume":"34","author":"Tejera-Vaquerizo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"zoi231665r21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma: part 2: treatment\u2014update 2022.","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi231665r22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s11606-019-05443-3","article-title":"Screening for melanoma in men: a cost-effectiveness analysis.","volume":"35","author":"Adamson","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi231665r24","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/hed.v42.6","article-title":"Potential impact of the COVID-19 pandemic on financial toxicity in cancer survivors.","volume":"42","author":"Baddour","year":"2020","journal-title":"Head Neck"},{"key":"zoi231665r25","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3332\/ecancer.2020.1134","article-title":"Cancer and COVID-19: economic impact on households in Southeast Asia.","volume":"14","author":"Kong","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"zoi231665r26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/bjd.v187.2","article-title":"Limited impact of COVID-19\u2013related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumour characteristics: a nationwide pathology registry analysis.","volume":"187","author":"Sangers","year":"2022","journal-title":"Br J Dermatol"},{"issue":"8","key":"zoi231665r27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(20)30388-0","article-title":"The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.","volume":"21","author":"Maringe","year":"2020","journal-title":"Lancet Oncol"},{"key":"zoi231665r28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/CCI.20.00068","article-title":"Effects of the COVID-19 pandemic on cancer-related patient encounters.","volume":"4","author":"London","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"10257","key":"zoi231665r29","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(20)32069-9","article-title":"Cancer and COVID-19.","volume":"396","author":"Moris","year":"2020","journal-title":"Lancet"},{"key":"zoi231665r30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1231436","article-title":"Finetuning of GLIDE stable diffusion model for AI-based text-conditional image synthesis of dermoscopic images.","volume":"10","author":"Shavlokhova","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"zoi231665r31","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1038\/s41598-021-83040-3","article-title":"Years of life lost to COVID-19 in 81 countries.","volume":"11","author":"Pifarr\u00e9 I Arolas","year":"2021","journal-title":"Sci Rep"},{"issue":"10100","key":"zoi231665r32","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"390","author":"GBD 2016 DALYs and HALE Collaborators","year":"2017","journal-title":"Lancet"},{"key":"zoi231665r12","first-page":"563","volume-title":"AJCC Cancer Staging Manual","author":"Gershenwald","year":"2017","edition":"8th ed"},{"key":"zoi231665r1","unstructured":"World Health Organization. Globocan 2020: Europe. Accessed July 15, 2023. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/908-europe-fact-sheets.pdf"},{"key":"zoi231665r9","unstructured":"National Disease Registration Service. Staging data in England. Accessed July 15, 2023. https:\/\/www.cancerdata.nhs.uk\/stage_at_diagnosis"},{"key":"zoi231665r10","unstructured":"National Health Service Wales. Cancer incidence in Wales: data tables. Accessed July 15, 2023. https:\/\/phw.nhs.wales\/services-and-teams\/welsh-cancer-intelligence-and-surveillance-unit-wcisu\/cancer-reporting-tool-official-statistics\/cancer-incidence\/cancer-incidence-documents\/data-tables\/"},{"key":"zoi231665r20","unstructured":"Spike? J. Hungary lifts some restrictions despite virus death spike. Associated Press. April 7, 2021. Accessed July 15, 2023. https:\/\/apnews.com\/article\/europe-budapest-viktor-orban-coronavirus-pandemic-hungary-9ae115804180b7c1267a176371ecf7c1"},{"key":"zoi231665r23","unstructured":"Australian Institute of Health and Welfare. Health expenditure Australia 2020-2021. Accessed November 17, 2023. https:\/\/www.aihw.gov.au\/reports\/health-welfare-expenditure\/health-expenditure-australia-2020-21\/contents\/summary"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2815226\/maul_2024_oi_231665_1707425483.67476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T16:31:30Z","timestamp":1708101090000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2815226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.56479","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}